LQDA (Liquidia) Short Interest


LQDA Liquidia Corp LQDA
67 GF Score
Price $76.91
GF Value $218.97
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LQDA vs HIMS, LNTH, INDV: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liquidia's Short Interest distribution charts can be found below:

* The bar in red indicates where Liquidia's Short Interest falls into.


LQDA
67GF Score
Liquidia Corp LQDA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $76.91 is trading 64.9% below its estimated GF Value™ of $218.97. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Short Interest:
  • GF Value™: $218.97 vs. price of $76.91 (64.9% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.91
Price
$218.97
GF Value